Xolair is effective in allergics with a low serum IgE level

International Archives of Allergy and Immunology

Volumn 152, Issue 1, 2010, Pages 71-74

  Ankerst, J ^a   Nopp, A ^b   Johansson, S G O ^b   Adedoyin J ^b   Oman H ^c  

^a Clinical Sciences ^*  (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MIAB   (Sweden)

Author keywords

Basophil; CD sens; IgE antibody; Low IgE level

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ADULT; ALLERGY; ARTICLE; ASTHMA; ATOPY; BASOPHIL; CASE REPORT; CLINICAL EVALUATION; CROSS REACTION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHINOCONJUNCTIVITIS; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; CATS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; MALE; TREATMENT OUTCOME;

EID: 70450173212     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000260086     Document Type: Article

References (12)

1. Xolair (omalizumab), summary of product characteristics. http://www.emea.eu.int/humandocs/ PDFs/EPAR/Xolair/H-606-PI-enpdf.
2. Johansson SGO, Nopp A, Öman H, Ankerst J, Cardell LO, Grönneberg R, et al.: The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair- ) treatment. Allergy 2009;64:1472-1477.
3. Johansson SGO, Öman H, Nopp A, Pettersson S: The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006; 61: 1216-1219.
4. Nopp A, Johansson SGO, Ankerst J, Bylin G, Cardell LO, Grönneberg R, et al.: Basophil allergen threshold sensitivity. A useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006; 61: 298-302.
5. Johansson SGO, Nopp A, van Hage M, Olofsson N, Lundahl J, Wehlin L, et al.: Passive IgE-sensitization by blood transfusion. Allergy 2005; 60: 1192-1199.
6. Kaplan AP, Greaves M: Pathogenesis of chronic urticaria. Clin Exp Allergy 2009; 39: 777-787.
7. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD: Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325: 1067-1071.
8. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S: Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101: 1483-1492.
9. Nopp A, Johansson SGO, Lundberg M, Öman H: Simultaneous exposure of several allergens has an additive effect on multisensitized basophils. Allergy 2006; 61: 1366-1368.
10. Nopp A, Johansson SGO, Ankerst J, Palmqvist M, Öman H: CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007; 62: 1175-1181.
11. Nopp A, Cardell LO, Johansson SGO, Öman H: CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy 2009; 64: 811-814.
12. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert- Margolis V, Asare A, Bateman K, Deniz Y: Omalizumab pre-treatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117: 134-140.